Page last updated: 2024-08-02 06:59:25

tws 119

Description

3-[[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol : no description available [CHeBI]

Cross-References

ID SourceID
PubMed CID90488884
PubMed CID9549289
CHEMBL ID405759
SCHEMBL ID5559045
CHEBI ID91384
MeSH IDM0544289

Synonyms (60)

Synonym
TWS 119 ,
3-[[6-(3-aminophenyl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxyphenol ditrifluoroacetate
1507095-58-0
AKOS024457823
xjefpmffwjtjsl-uhfffaoysa-n
3-((6-(3-aminophenyl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenol bis(2,2,2-trifluoroacetate)
A935282
3-[[6-(3-aminophenyl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol;2,2,2-trifluoroacetic acid
BT162778
gsk inhibitor xii
K00245 ,
HY-10590
BRD-K94176593-001-01-1
HSCI1_000361
CHEMBL405759 ,
tws-119
HMS3229M16
3-(6-(3-aminophenyl)-7h-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol
bdbm50325986
3-{[6-(3-aminophenyl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol
TWS119 ,
BCPP000029
601514-19-6
NCGC00346638-01
PB22215
CS-0224
S1590
3-[[6-(3-aminophenyl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol
gtpl5980
gsk-3beta inhibitor xii
CCG-206847
smr004702816
MLS006011018
AKOS016368735
SCHEMBL5559045
3-[6-(3-amino-phenyl)-7h-pyrrolo[2,3-d]pyrimidin-4-yloxy]-phenol
VPVLEBIVXZSOMQ-UHFFFAOYSA-N
3-[6-(3-amino-phenyl)-7h-pyrrolo[2,3,-d]pyrimidin-4-yloxy]-phenol
DTXSID00429550
phenol, 3-[[6-(3-aminophenyl)-1h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-
3-((6-(3-aminophenyl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenol
AC-32688
AKOS028109054
J-511451
EX-A151
CHEBI:91384
HMS3655M07
mfcd09037535
AS-71680
tws119, >=98% (hplc)
NCGC00346638-07
SW219785-1
gsk-3beta inhibitor xii, tws119 - cas 601514-19-6
FT-0700339
Q27089039
BCP02458
HMS3295C11
A869036
gsk-3 beta inhibitor xii, tws119
Z3039181534

Drug Classes (1)

ClassDescription
pyrrolesAn azole that includes only one N atom and no other heteroatom as a part of the aromatic skeleton.

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency13.1373AID1347411
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency8.4866AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency3.1997AID1259252; AID1259253; AID1259255; AID1259256
GVesicular stomatitis virusPotency23.9185AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency11.9877AID1645840
Interferon betaHomo sapiens (human)Potency15.8326AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency23.9185AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency23.9185AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency23.9185AID1645842

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Myc proto-oncogene proteinGallus gallus (chicken)IC5015.0000AID512621
Transcription factor AP-1Gallus gallus (chicken)IC5015.0000AID512621
Interferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)IC504.0000AID606664
Glycogen synthase kinase-3 betaHomo sapiens (human)IC500.0300AID1645916; AID1727768; AID512484
Glycogen synthase kinase-3 betaMus musculus (house mouse)IC500.0300AID512622

Activation Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Glycogen synthase kinase-3 betaMus musculus (house mouse)EC501.0000AID512612; AID512613; AID512614
Glycogen synthase kinase-3 betaMus musculus (house mouse)Kd0.1260AID512611

Bioassays (573)

Assay IDTitleYearJournalArticle
AID720284Millipore: Percentage of residual kinase activity of MAP3K7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720259Millipore: Percentage of residual kinase activity of MAPK14 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720154Millipore: Percentage of residual kinase activity of FGFR3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720436Millipore: Percentage of residual kinase activity of RPS6KB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720484Millipore: Percentage of residual kinase activity of PRKCZ at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720336Millipore: Percentage of residual kinase activity of LYN at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224791Delta TM value showing the stabilisation of PRKACA produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720481Millipore: Percentage of residual kinase activity of PRKCD at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720023Millipore: Percentage of residual kinase activity of PRKAA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720297Millipore: Percentage of residual kinase activity of IGF1R at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720070Millipore: Percentage of residual kinase activity of CDK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720089Millipore: Percentage of residual kinase activity of CLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720211Millipore: Percentage of residual kinase activity of PRKG1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720097Millipore: Percentage of residual kinase activity of CAMK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720335Millipore: Percentage of residual kinase activity of LCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224807Delta TM value showing the stabilisation of YSK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720214Millipore: Percentage of residual kinase activity of MAPKAPK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720086Millipore: Percentage of residual kinase activity of CSNK2A1 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720091Millipore: Percentage of residual kinase activity of CLK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720161Millipore: Percentage of residual kinase activity of FGR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720095Millipore: Percentage of residual kinase activity of CAMK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720370Millipore: Percentage of residual kinase activity of SRPK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720416Millipore: Percentage of residual kinase activity of WNK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224758Delta TM value showing the stabilisation of CDK6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720215Millipore: Percentage of residual kinase activity of MAPKAPK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512622Binding affinity to GSK-3 beta in mouse D3 cells2005Nature chemical biology, Jul, Volume: 1, Issue:2
ISSN: 1552-4450
Diversity-oriented synthesis: exploring the intersections between chemistry and biology.
AID720074Millipore: Percentage of residual kinase activity of CHEK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720342Millipore: Percentage of residual kinase activity of MAPKAPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720166Millipore: Percentage of residual kinase activity of FLT3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720302Millipore: Percentage of residual kinase activity of INSR at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720281Millipore: Percentage of residual kinase activity of PLK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224785Delta TM value showing the stabilisation of PDK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720264Millipore: Percentage of residual kinase activity of MAPK13 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720431Millipore: Percentage of residual kinase activity of EEF2K at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224781Delta TM value showing the stabilisation of PAK4 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720235Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720384Millipore: Percentage of residual kinase activity of MUSK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720426Millipore: Percentage of residual kinase activity of KIT at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720098Millipore: Percentage of residual kinase activity of CAMK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720111Millipore: Percentage of residual kinase activity of DCLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720245Millipore: Percentage of residual kinase activity of MST1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720272Millipore: Percentage of residual kinase activity of SIK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720258Millipore: Percentage of residual kinase activity of MAPK14 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720269Millipore: Percentage of residual kinase activity of SGK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720290Millipore: Percentage of residual kinase activity of TAOK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224757Delta TM value showing the stabilisation of CDK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720051Millipore: Percentage of residual kinase activity of BRSK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720365Millipore: Percentage of residual kinase activity of CDC42BPB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720285Millipore: Percentage of residual kinase activity of MAP3K7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720197Millipore: Percentage of residual kinase activity of IGF1R at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720147Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720040Millipore: Percentage of residual kinase activity of AURKC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720313Millipore: Percentage of residual kinase activity of ITK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720310Millipore: Percentage of residual kinase activity of INSRR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720180Millipore: Percentage of residual kinase activity of GRK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720250Millipore: Percentage of residual kinase activity of RPS6KA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720088Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720465Millipore: Percentage of residual kinase activity of PRKACA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720020Millipore: Percentage of residual kinase activity of ALK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720141Millipore: Percentage of residual kinase activity of EPHB3 at 1uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720063Millipore: Percentage of residual kinase activity of CDK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720112Millipore: Percentage of residual kinase activity of DCLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720402Millipore: Percentage of residual kinase activity of NTRK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720104Millipore: Percentage of residual kinase activity of CAMK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 40 mM HEPES pH 7.4, 5 mM CaCl2, 30 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720243Millipore: Percentage of residual kinase activity of RET at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720327Millipore: Percentage of residual kinase activity of LIMK1 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720466Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720464Millipore: Percentage of residual kinase activity of PRKACA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720275Millipore: Percentage of residual kinase activity of SRPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720139Millipore: Percentage of residual kinase activity of EPHB2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720463Millipore: Percentage of residual kinase activity of PDPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512614Inhibition of GSK-3 beta in mouse D3 cells assessed as induction of neuron specific marker beta3-tubulin by immunofluorescence method2005Nature chemical biology, Jul, Volume: 1, Issue:2
ISSN: 1552-4450
Diversity-oriented synthesis: exploring the intersections between chemistry and biology.
AID720230Millipore: Percentage of residual kinase activity of PLK3 at 1uM relative to control. Control inhibitor: Wortmannin at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720314Millipore: Percentage of residual kinase activity of JAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720018Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720144Millipore: Percentage of residual kinase activity of EPHB4 at 10uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720068Millipore: Percentage of residual kinase activity of CDK6 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720283Millipore: Percentage of residual kinase activity of SYK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720193Millipore: Percentage of residual kinase activity of HCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720276Millipore: Percentage of residual kinase activity of SRPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720316Millipore: Percentage of residual kinase activity of JAK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224804Delta TM value showing the stabilisation of VRK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720472Millipore: Percentage of residual kinase activity of PRKCA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720155Millipore: Percentage of residual kinase activity of FGFR4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720115Millipore: Percentage of residual kinase activity of DMPK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224753Delta TM value showing the stabilisation of CAMK2D produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224789Delta TM value showing the stabilisation of PLK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720078Millipore: Percentage of residual kinase activity of CSNK1G1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720186Millipore: Percentage of residual kinase activity of HIPK1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720123Millipore: Percentage of residual kinase activity of EPHA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224770Delta TM value showing the stabilisation of JAK1~B produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720447Millipore: Percentage of residual kinase activity of PAK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720067Millipore: Percentage of residual kinase activity of CDK6 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720128Millipore: Percentage of residual kinase activity of EPHA3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720439Millipore: Percentage of residual kinase activity of NEK6 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720152Millipore: Percentage of residual kinase activity of FGFR2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720307Millipore: Percentage of residual kinase activity of IRAK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720017Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720443Millipore: Percentage of residual kinase activity of NLK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720363Millipore: Percentage of residual kinase activity of CDC42BPA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720066Millipore: Percentage of residual kinase activity of CDK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720473Millipore: Percentage of residual kinase activity of PRKCA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720478Millipore: Percentage of residual kinase activity of PRKCG at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720219Millipore: Percentage of residual kinase activity of FRK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720399Millipore: Percentage of residual kinase activity of TEC at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720042Millipore: Percentage of residual kinase activity of AXL at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720172Millipore: Percentage of residual kinase activity of FYN at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720349Millipore: Percentage of residual kinase activity of MAP2K1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% ?-mercaptoethanol, 0.01% Brij-352013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720062Millipore: Percentage of residual kinase activity of CDK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720271Millipore: Percentage of residual kinase activity of SGK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720178Millipore: Percentage of residual kinase activity of GRK6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720382Millipore: Percentage of residual kinase activity of MKNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720253Millipore: Percentage of residual kinase activity of RPS6KA3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720470Millipore: Percentage of residual kinase activity of AKT3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720388Millipore: Percentage of residual kinase activity of NEK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720329Millipore: Percentage of residual kinase activity of STK11 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% v/v Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720052Millipore: Percentage of residual kinase activity of BRSK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720081Millipore: Percentage of residual kinase activity of CSNK1G3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720170Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720184Millipore: Percentage of residual kinase activity of GSK3B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720348Millipore: Percentage of residual kinase activity of MAP2K1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% ?-mercaptoethanol, 0.01% Brij-352013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224768Delta TM value showing the stabilisation of DMPK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720414Millipore: Percentage of residual kinase activity of WNK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720240Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720236Millipore: Percentage of residual kinase activity of RIPK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720126Millipore: Percentage of residual kinase activity of EPHA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720404Millipore: Percentage of residual kinase activity of NTRK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720053Millipore: Percentage of residual kinase activity of BRSK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224760Delta TM value showing the stabilisation of CHEK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224802Delta TM value showing the stabilisation of TNIK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224780Delta TM value showing the stabilisation of OSR1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224803Delta TM value showing the stabilisation of PBK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720136Millipore: Percentage of residual kinase activity of EPHA8 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720137Millipore: Percentage of residual kinase activity of EPHB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720024Millipore: Percentage of residual kinase activity of PRKAA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224774Delta TM value showing the stabilisation of p38beta produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720369Millipore: Percentage of residual kinase activity of RPS6KA4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720417Millipore: Percentage of residual kinase activity of WNK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720409Millipore: Percentage of residual kinase activity of ULK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720226Millipore: Percentage of residual kinase activity of PIM3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720328Millipore: Percentage of residual kinase activity of STK11 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% v/v Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1727768Inhibition of GSK3beta (unknown origin)2021European journal of medicinal chemistry, Jan-15, Volume: 210ISSN: 1768-3254PROTACs suppression of GSK-3β, a crucial kinase in neurodegenerative diseases.
AID325785Induction of differentiation in mouse D3 cells at 400 nM2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720479Millipore: Percentage of residual kinase activity of PRKCG at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720096Millipore: Percentage of residual kinase activity of CAMK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720324Millipore: Percentage of residual kinase activity of KDR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720120Millipore: Percentage of residual kinase activity of DYRK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720187Millipore: Percentage of residual kinase activity of HIPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720274Millipore: Percentage of residual kinase activity of SRPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720391Millipore: Percentage of residual kinase activity of NEK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224771Delta TM value showing the stabilisation of MEK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720138Millipore: Percentage of residual kinase activity of EPHB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720029Millipore: Percentage of residual kinase activity of MAP3K5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720234Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720239Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720320Millipore: Percentage of residual kinase activity of MAPK9 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720160Millipore: Percentage of residual kinase activity of FES at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720167Millipore: Percentage of residual kinase activity of FLT4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720247Millipore: Percentage of residual kinase activity of ROS1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720346Millipore: Percentage of residual kinase activity of MARK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720421Millipore: Percentage of residual kinase activity of ZAP70 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720228Millipore: Percentage of residual kinase activity of PLK1 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720425Millipore: Percentage of residual kinase activity of RAF1 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720477Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720359Millipore: Percentage of residual kinase activity of MYLK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512621Inhibition of Myc-Jun protein - protein interaction in chicken embryo fibroblasts assessed as inhibition of cell focus formation112005Nature chemical biology, Jul, Volume: 1, Issue:2
ISSN: 1552-4450
Diversity-oriented synthesis: exploring the intersections between chemistry and biology.
AID720232Millipore: Percentage of residual kinase activity of PRKX at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720411Millipore: Percentage of residual kinase activity of ULK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720199Millipore: Percentage of residual kinase activity of PRKCZ at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720028Millipore: Percentage of residual kinase activity of NUAK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720073Millipore: Percentage of residual kinase activity of CHEK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720202Millipore: Percentage of residual kinase activity of PRKCQ at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720415Millipore: Percentage of residual kinase activity of WNK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720347Millipore: Percentage of residual kinase activity of MARK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224751Delta TM value showing the stabilisation of CAMK2A produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224788Delta TM value showing the stabilisation of PIM3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224776Delta TM value showing the stabilisation of ERK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720036Millipore: Percentage of residual kinase activity of AURKA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720143Millipore: Percentage of residual kinase activity of EPHB4 at 1uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720289Millipore: Percentage of residual kinase activity of TAOK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720148Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720410Millipore: Percentage of residual kinase activity of ULK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720305Millipore: Percentage of residual kinase activity of INSR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720064Millipore: Percentage of residual kinase activity of CDK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720019Millipore: Percentage of residual kinase activity of ALK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720254Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720354Millipore: Percentage of residual kinase activity of MAP2K6 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4, 1 mg/mL BSA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720049Millipore: Percentage of residual kinase activity of BMX at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720270Millipore: Percentage of residual kinase activity of SGK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720295Millipore: Percentage of residual kinase activity of TGFBR1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720146Millipore: Percentage of residual kinase activity of ERBB4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720376Millipore: Percentage of residual kinase activity of STK24 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720333Millipore: Percentage of residual kinase activity of LCK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720246Millipore: Percentage of residual kinase activity of ROS1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720292Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720131Millipore: Percentage of residual kinase activity of EPHA5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720065Millipore: Percentage of residual kinase activity of CDK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720306Millipore: Percentage of residual kinase activity of IRAK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720031Millipore: Percentage of residual kinase activity of ABL1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720273Millipore: Percentage of residual kinase activity of SIK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720109Millipore: Percentage of residual kinase activity of DAPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720454Millipore: Percentage of residual kinase activity of MARK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224797Delta TM value showing the stabilisation of MPSK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720311Millipore: Percentage of residual kinase activity of INSRR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720356Millipore: Percentage of residual kinase activity of MAP2K7 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720394Millipore: Percentage of residual kinase activity of TSSK1B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720299Millipore: Percentage of residual kinase activity of CHUK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720222Millipore: Percentage of residual kinase activity of PIM1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720075Millipore: Percentage of residual kinase activity of CHEK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720471Millipore: Percentage of residual kinase activity of AKT3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720082Millipore: Percentage of residual kinase activity of CSNK1G3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720072Millipore: Percentage of residual kinase activity of CDK9 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720362Millipore: Percentage of residual kinase activity of CDC42BPA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720287Millipore: Percentage of residual kinase activity of TAOK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720468Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720125Millipore: Percentage of residual kinase activity of EPHA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720179Millipore: Percentage of residual kinase activity of GRK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720334Millipore: Percentage of residual kinase activity of LCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720338Millipore: Percentage of residual kinase activity of MAPK3 at 1uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720373Millipore: Percentage of residual kinase activity of STK4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720105Millipore: Percentage of residual kinase activity of CAMK1D at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720268Millipore: Percentage of residual kinase activity of SGK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720225Millipore: Percentage of residual kinase activity of PIM2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720034Millipore: Percentage of residual kinase activity of ABL2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720442Millipore: Percentage of residual kinase activity of NLK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720282Millipore: Percentage of residual kinase activity of SYK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720255Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720099Millipore: Percentage of residual kinase activity of CAMK2G at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720437Millipore: Percentage of residual kinase activity of RPS6KB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720277Millipore: Percentage of residual kinase activity of SRPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224794Delta TM value showing the stabilisation of RSK2b produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720461Millipore: Percentage of residual kinase activity of PDGFRB at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720355Millipore: Percentage of residual kinase activity of MAP2K6 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4, 1 mg/mL BSA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720405Millipore: Percentage of residual kinase activity of NTRK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720389Millipore: Percentage of residual kinase activity of NEK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720149Millipore: Percentage of residual kinase activity of FGFR1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720457Millipore: Percentage of residual kinase activity of PASK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720344Millipore: Percentage of residual kinase activity of MAPKAPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720460Millipore: Percentage of residual kinase activity of PDGFRB at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720262Millipore: Percentage of residual kinase activity of MAPK12 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720381Millipore: Percentage of residual kinase activity of MET at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720021Millipore: Percentage of residual kinase activity of ACVR1B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720429Millipore: Percentage of residual kinase activity of SRC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720122Millipore: Percentage of residual kinase activity of EGFR at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720450Millipore: Percentage of residual kinase activity of PAK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720227Millipore: Percentage of residual kinase activity of PIM3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID325784Induction of differentiation in mouse P19 cells at 1000 nM2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720192Millipore: Percentage of residual kinase activity of GSG2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720331Millipore: Percentage of residual kinase activity of STK10 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720326Millipore: Percentage of residual kinase activity of LIMK1 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720462Millipore: Percentage of residual kinase activity of PDPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720085Millipore: Percentage of residual kinase activity of CSNK2A1 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720458Millipore: Percentage of residual kinase activity of PDGFRA at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224765Delta TM value showing the stabilisation of CK1G2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720077Millipore: Percentage of residual kinase activity of CSNK1G1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224779Delta TM value showing the stabilisation of NEK6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720406Millipore: Percentage of residual kinase activity of TXK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720383Millipore: Percentage of residual kinase activity of MKNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720377Millipore: Percentage of residual kinase activity of STK24 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720207Millipore: Percentage of residual kinase activity of PRKD1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720241Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224755Delta TM value showing the stabilisation of CAMK4 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720188Millipore: Percentage of residual kinase activity of HIPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720380Millipore: Percentage of residual kinase activity of MET at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720386Millipore: Percentage of residual kinase activity of NEK11 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224775Delta TM value showing the stabilisation of ERK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720182Millipore: Percentage of residual kinase activity of GSK3A at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720263Millipore: Percentage of residual kinase activity of MAPK12 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720422Millipore: Percentage of residual kinase activity of DAPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720423Millipore: Percentage of residual kinase activity of DAPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720339Millipore: Percentage of residual kinase activity of MAPK3 at 10uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224778Delta TM value showing the stabilisation of NEK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720054Millipore: Percentage of residual kinase activity of BRSK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720025Millipore: Percentage of residual kinase activity of PRKAA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224790Delta TM value showing the stabilisation of PLK4 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720056Millipore: Percentage of residual kinase activity of CDK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720378Millipore: Percentage of residual kinase activity of MERTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720332Millipore: Percentage of residual kinase activity of LCK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720213Millipore: Percentage of residual kinase activity of PRKG1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720183Millipore: Percentage of residual kinase activity of GSK3B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720174Millipore: Percentage of residual kinase activity of GCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720061Millipore: Percentage of residual kinase activity of CDK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720413Millipore: Percentage of residual kinase activity of VRK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720248Millipore: Percentage of residual kinase activity of TYRO3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720027Millipore: Percentage of residual kinase activity of NUAK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720280Millipore: Percentage of residual kinase activity of PLK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720165Millipore: Percentage of residual kinase activity of FLT3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720340Millipore: Percentage of residual kinase activity of MAPK1 at 1uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720084Millipore: Percentage of residual kinase activity of CSNK1D at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720127Millipore: Percentage of residual kinase activity of EPHA3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720242Millipore: Percentage of residual kinase activity of RET at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720191Millipore: Percentage of residual kinase activity of GSG2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720135Millipore: Percentage of residual kinase activity of EPHA8 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720190Millipore: Percentage of residual kinase activity of HIPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720238Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720251Millipore: Percentage of residual kinase activity of RPS6KA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512613Inhibition of GSK-3 beta in mouse D3 cells assessed as induction of neuron specific marker neurofilament-M by immunofluorescence method2005Nature chemical biology, Jul, Volume: 1, Issue:2
ISSN: 1552-4450
Diversity-oriented synthesis: exploring the intersections between chemistry and biology.
AID720076Millipore: Percentage of residual kinase activity of CHEK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720217Millipore: Percentage of residual kinase activity of PKN2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720291Millipore: Percentage of residual kinase activity of TAOK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720360Millipore: Percentage of residual kinase activity of MAP3K9 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720163Millipore: Percentage of residual kinase activity of FLT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720150Millipore: Percentage of residual kinase activity of FGFR1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720449Millipore: Percentage of residual kinase activity of PAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720116Millipore: Percentage of residual kinase activity of DMPK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720033Millipore: Percentage of residual kinase activity of ABL2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720260Millipore: Percentage of residual kinase activity of MAPK11 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224801Delta TM value showing the stabilisation of MST1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720474Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720446Millipore: Percentage of residual kinase activity of PAK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512611Inhibition of GSK-3 beta in mouse D3 cells2005Nature chemical biology, Jul, Volume: 1, Issue:2
ISSN: 1552-4450
Diversity-oriented synthesis: exploring the intersections between chemistry and biology.
AID720130Millipore: Percentage of residual kinase activity of EPHA4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224766Delta TM value showing the stabilisation of CK1G3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720325Millipore: Percentage of residual kinase activity of KDR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224787Delta TM value showing the stabilisation of PIM2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720176Millipore: Percentage of residual kinase activity of GRK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720296Millipore: Percentage of residual kinase activity of IGF1R at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720153Millipore: Percentage of residual kinase activity of FGFR3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512612Inhibition of GSK-3 beta in mouse D3 cells assessed as induction of neuron specific marker microtubule-associated protein 2 by immunofluorescence method2005Nature chemical biology, Jul, Volume: 1, Issue:2
ISSN: 1552-4450
Diversity-oriented synthesis: exploring the intersections between chemistry and biology.
AID1224784Delta TM value showing the stabilisation of PCTK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720079Millipore: Percentage of residual kinase activity of CSNK1G2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720204Millipore: Percentage of residual kinase activity of PRKCI at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720294Millipore: Percentage of residual kinase activity of TGFBR1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720395Millipore: Percentage of residual kinase activity of TSSK1B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720445Millipore: Percentage of residual kinase activity of PAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720343Millipore: Percentage of residual kinase activity of MAPKAPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224783Delta TM value showing the stabilisation of PAK6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720069Millipore: Percentage of residual kinase activity of CDK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720041Millipore: Percentage of residual kinase activity of AXL at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720375Millipore: Percentage of residual kinase activity of STK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720101Millipore: Percentage of residual kinase activity of CAMK2D at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720118Millipore: Percentage of residual kinase activity of STK17A at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720397Millipore: Percentage of residual kinase activity of TSSK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720434Millipore: Percentage of residual kinase activity of MTOR at 1uM relative to control. Control inhibitor: Rapamycin at 10.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20, 10 uM FKBP122013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720390Millipore: Percentage of residual kinase activity of NEK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID606664Inhibition of human recombinant PKR autophosphorylation using poly[I:C] after 10 mins by luminescent assay2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
ISSN: 1464-3405
Identification of new inhibitors of protein kinase R guided by statistical modeling.
AID720286Millipore: Percentage of residual kinase activity of TAOK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720175Millipore: Percentage of residual kinase activity of GRK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720159Millipore: Percentage of residual kinase activity of FES at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720482Millipore: Percentage of residual kinase activity of PRKCE at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720428Millipore: Percentage of residual kinase activity of SRC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224754Delta TM value showing the stabilisation of CAMK2G produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720432Millipore: Percentage of residual kinase activity of MTOR at 1uM relative to control. Control inhibitor: PI-103 at 30.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 202013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720308Millipore: Percentage of residual kinase activity of IRAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720151Millipore: Percentage of residual kinase activity of FGFR2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720087Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224764Delta TM value showing the stabilisation of CK1G1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720171Millipore: Percentage of residual kinase activity of FYN at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720427Millipore: Percentage of residual kinase activity of KIT at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720469Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720094Millipore: Percentage of residual kinase activity of CSK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720279Millipore: Percentage of residual kinase activity of STK33 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224749Delta TM value showing the stabilisation of CAMK1D produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720181Millipore: Percentage of residual kinase activity of GSK3A at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720317Millipore: Percentage of residual kinase activity of JAK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720438Millipore: Percentage of residual kinase activity of NEK6 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720337Millipore: Percentage of residual kinase activity of LYN at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720038Millipore: Percentage of residual kinase activity of AURKB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720216Millipore: Percentage of residual kinase activity of PKN2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720361Millipore: Percentage of residual kinase activity of MAP3K9 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720483Millipore: Percentage of residual kinase activity of PRKCE at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720110Millipore: Percentage of residual kinase activity of DAPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720157Millipore: Percentage of residual kinase activity of FER at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720387Millipore: Percentage of residual kinase activity of NEK11 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720208Millipore: Percentage of residual kinase activity of PRKD2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720223Millipore: Percentage of residual kinase activity of PIM1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720352Millipore: Percentage of residual kinase activity of MINK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720050Millipore: Percentage of residual kinase activity of BMX at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720224Millipore: Percentage of residual kinase activity of PIM2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720205Millipore: Percentage of residual kinase activity of PRKCI at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720103Millipore: Percentage of residual kinase activity of CAMK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 40 mM HEPES pH 7.4, 5 mM CaCl2, 30 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720298Millipore: Percentage of residual kinase activity of CHUK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720396Millipore: Percentage of residual kinase activity of TSSK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720419Millipore: Percentage of residual kinase activity of YES1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720350Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720206Millipore: Percentage of residual kinase activity of PRKD1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720312Millipore: Percentage of residual kinase activity of ITK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224800Delta TM value showing the stabilisation of MST4 (2) produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720374Millipore: Percentage of residual kinase activity of STK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720113Millipore: Percentage of residual kinase activity of DDR2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720083Millipore: Percentage of residual kinase activity of CSNK1D at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224752Delta TM value showing the stabilisation of CAMK2B produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720117Millipore: Percentage of residual kinase activity of STK17A at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720420Millipore: Percentage of residual kinase activity of ZAP70 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224763Delta TM value showing the stabilisation of CLK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720367Millipore: Percentage of residual kinase activity of RPS6KA5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720408Millipore: Percentage of residual kinase activity of ULK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720398Millipore: Percentage of residual kinase activity of TEC at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720162Millipore: Percentage of residual kinase activity of FGR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720231Millipore: Percentage of residual kinase activity of PLK3 at 10uM relative to control. Control inhibitor: Wortmannin at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720090Millipore: Percentage of residual kinase activity of CLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720300Millipore: Percentage of residual kinase activity of IKBKB at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720119Millipore: Percentage of residual kinase activity of DYRK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720407Millipore: Percentage of residual kinase activity of TXK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720266Millipore: Percentage of residual kinase activity of SGK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720256Millipore: Percentage of residual kinase activity of RPS6KA6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720129Millipore: Percentage of residual kinase activity of EPHA4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720221Millipore: Percentage of residual kinase activity of PHKG2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720055Millipore: Percentage of residual kinase activity of CDK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720158Millipore: Percentage of residual kinase activity of FER at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720114Millipore: Percentage of residual kinase activity of DDR2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720140Millipore: Percentage of residual kinase activity of EPHB2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224795Delta TM value showing the stabilisation of SLK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224782Delta TM value showing the stabilisation of PAK5 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720043Millipore: Percentage of residual kinase activity of PTK6 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720322Millipore: Percentage of residual kinase activity of MAPK10 at 1uM relative to control. Control inhibitor: JAK Inhibitor I at 30.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720455Millipore: Percentage of residual kinase activity of MARK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720364Millipore: Percentage of residual kinase activity of CDC42BPB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224806Delta TM value showing the stabilisation of VRK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720106Millipore: Percentage of residual kinase activity of CAMK1D at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720288Millipore: Percentage of residual kinase activity of TAOK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720293Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720210Millipore: Percentage of residual kinase activity of PRKG1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720058Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720379Millipore: Percentage of residual kinase activity of MERTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720418Millipore: Percentage of residual kinase activity of YES1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1645916Inhibition of Glycogen synthase kinase-3 beta (unknown origin)2019European journal of medicinal chemistry, Feb-15, Volume: 164ISSN: 1768-3254Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3β inhibitors: A critical review.
AID720315Millipore: Percentage of residual kinase activity of JAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720400Millipore: Percentage of residual kinase activity of TEK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224773Delta TM value showing the stabilisation of ASK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720385Millipore: Percentage of residual kinase activity of MUSK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720071Millipore: Percentage of residual kinase activity of CDK9 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720456Millipore: Percentage of residual kinase activity of PASK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720093Millipore: Percentage of residual kinase activity of CSK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720177Millipore: Percentage of residual kinase activity of GRK6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720430Millipore: Percentage of residual kinase activity of EEF2K at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224805Delta TM value showing the stabilisation of VRK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720453Millipore: Percentage of residual kinase activity of PAK6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720237Millipore: Percentage of residual kinase activity of RIPK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720022Millipore: Percentage of residual kinase activity of ACVR1B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720366Millipore: Percentage of residual kinase activity of RPS6KA5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720057Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720265Millipore: Percentage of residual kinase activity of MAPK13 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720267Millipore: Percentage of residual kinase activity of SGK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720330Millipore: Percentage of residual kinase activity of STK10 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720039Millipore: Percentage of residual kinase activity of AURKC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224796Delta TM value showing the stabilisation of LOK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720060Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720353Millipore: Percentage of residual kinase activity of MINK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720201Millipore: Percentage of residual kinase activity of PRKCH at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720451Millipore: Percentage of residual kinase activity of PAK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720195Millipore: Percentage of residual kinase activity of HCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720045Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720392Millipore: Percentage of residual kinase activity of TLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720467Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720321Millipore: Percentage of residual kinase activity of MAPK9 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720218Millipore: Percentage of residual kinase activity of FRK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720189Millipore: Percentage of residual kinase activity of HIPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720401Millipore: Percentage of residual kinase activity of TEK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224756Delta TM value showing the stabilisation of CAMKK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720323Millipore: Percentage of residual kinase activity of MAPK10 at 10uM relative to control. Control inhibitor: JAK Inhibitor I at 30.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720278Millipore: Percentage of residual kinase activity of STK33 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720196Millipore: Percentage of residual kinase activity of HCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720198Millipore: Percentage of residual kinase activity of IGF1R at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512484Inhibition of GSK3-beta2004Trends in pharmacological sciences, Sep, Volume: 25, Issue:9
ISSN: 0165-6147
Pharmacological inhibitors of glycogen synthase kinase 3.
AID720133Millipore: Percentage of residual kinase activity of EPHA7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720476Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720035Millipore: Percentage of residual kinase activity of AURKA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720452Millipore: Percentage of residual kinase activity of PAK6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720358Millipore: Percentage of residual kinase activity of MYLK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720424Millipore: Percentage of residual kinase activity of RAF1 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224748Delta TM value showing the stabilisation of AMPKA2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720357Millipore: Percentage of residual kinase activity of MAP2K7 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224750Delta TM value showing the stabilisation of CAMK1G produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720092Millipore: Percentage of residual kinase activity of CLK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720194Millipore: Percentage of residual kinase activity of HCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720304Millipore: Percentage of residual kinase activity of INSR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224761Delta TM value showing the stabilisation of CLK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720220Millipore: Percentage of residual kinase activity of PHKG2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720441Millipore: Percentage of residual kinase activity of NEK7 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720435Millipore: Percentage of residual kinase activity of MTOR at 10uM relative to control. Control inhibitor: Rapamycin at 10.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20, 10 uM FKBP122013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720459Millipore: Percentage of residual kinase activity of PDGFRA at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224762Delta TM value showing the stabilisation of CLK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720233Millipore: Percentage of residual kinase activity of PRKX at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224767Delta TM value showing the stabilisation of DAPK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720185Millipore: Percentage of residual kinase activity of HIPK1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224799Delta TM value showing the stabilisation of NDR1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720209Millipore: Percentage of residual kinase activity of PRKD2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720048Millipore: Percentage of residual kinase activity of BLK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224786Delta TM value showing the stabilisation of PIM1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224777Delta TM value showing the stabilisation of MST4(1) produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224793Delta TM value showing the stabilisation of RSK2a produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720121Millipore: Percentage of residual kinase activity of EGFR at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720319Millipore: Percentage of residual kinase activity of MAPK8 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ? -mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720102Millipore: Percentage of residual kinase activity of CAMK2D at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720044Millipore: Percentage of residual kinase activity of PTK6 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224798Delta TM value showing the stabilisation of DRAK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720080Millipore: Percentage of residual kinase activity of CSNK1G2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720169Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720203Millipore: Percentage of residual kinase activity of PRKCQ at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224759Delta TM value showing the stabilisation of CDKL1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720303Millipore: Percentage of residual kinase activity of INSR at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720244Millipore: Percentage of residual kinase activity of MST1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720444Millipore: Percentage of residual kinase activity of PAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720046Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720309Millipore: Percentage of residual kinase activity of IRAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720403Millipore: Percentage of residual kinase activity of NTRK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720345Millipore: Percentage of residual kinase activity of MAPKAPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720440Millipore: Percentage of residual kinase activity of NEK7 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224792Delta TM value showing the stabilisation of RIOK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720200Millipore: Percentage of residual kinase activity of PRKCH at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720134Millipore: Percentage of residual kinase activity of EPHA7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720252Millipore: Percentage of residual kinase activity of RPS6KA3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720100Millipore: Percentage of residual kinase activity of CAMK2G at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720156Millipore: Percentage of residual kinase activity of FGFR4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720173Millipore: Percentage of residual kinase activity of GCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720212Millipore: Percentage of residual kinase activity of PRKG1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720318Millipore: Percentage of residual kinase activity of MAPK8 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ? -mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720249Millipore: Percentage of residual kinase activity of TYRO3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720257Millipore: Percentage of residual kinase activity of RPS6KA6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720412Millipore: Percentage of residual kinase activity of VRK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720448Millipore: Percentage of residual kinase activity of PAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720480Millipore: Percentage of residual kinase activity of PRKCD at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720229Millipore: Percentage of residual kinase activity of PLK1 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720145Millipore: Percentage of residual kinase activity of ERBB4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720301Millipore: Percentage of residual kinase activity of IKBKB at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720372Millipore: Percentage of residual kinase activity of STK4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224769Delta TM value showing the stabilisation of GSK3B produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720371Millipore: Percentage of residual kinase activity of SRPK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720475Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720393Millipore: Percentage of residual kinase activity of TLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720108Millipore: Percentage of residual kinase activity of DAPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720164Millipore: Percentage of residual kinase activity of FLT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720047Millipore: Percentage of residual kinase activity of BLK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720351Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720032Millipore: Percentage of residual kinase activity of ABL1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720261Millipore: Percentage of residual kinase activity of MAPK11 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720341Millipore: Percentage of residual kinase activity of MAPK1 at 10uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720168Millipore: Percentage of residual kinase activity of FLT4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224772Delta TM value showing the stabilisation of MAP2K6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
ISSN: 1091-6490
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720124Millipore: Percentage of residual kinase activity of EPHA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720107Millipore: Percentage of residual kinase activity of DAPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720059Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720037Millipore: Percentage of residual kinase activity of AURKB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720132Millipore: Percentage of residual kinase activity of EPHA5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720030Millipore: Percentage of residual kinase activity of MAP3K5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720026Millipore: Percentage of residual kinase activity of PRKAA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720368Millipore: Percentage of residual kinase activity of RPS6KA4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720433Millipore: Percentage of residual kinase activity of MTOR at 10uM relative to control. Control inhibitor: PI-103 at 30.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 202013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720142Millipore: Percentage of residual kinase activity of EPHB3 at 10uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
ISSN: 1470-8728
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173ISSN: 1872-9096A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173ISSN: 1872-9096A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression2022The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
ISSN: 2211-1247
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173ISSN: 1872-9096A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1345633Human glycogen synthase kinase 3 beta (GSK subfamily)2003Proceedings of the National Academy of Sciences of the United States of America, Jun-24, Volume: 100, Issue:13
ISSN: 0027-8424
Synthetic small molecules that control stem cell fate.

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (10.53)29.6817
2010's24 (63.16)24.3611
2020's10 (26.32)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (10.53%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other34 (89.47%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
porphobilinogenaralkylamino compound;
dicarboxylic acid;
pyrroles
Escherichia coli metabolite;
metabolite;
mouse metabolite
00low000000
fpl 64176carboxylic ester;
pyrroles
calcium channel agonist00low000000
SU5402monocarboxylic acid;
oxindoles;
pyrroles
fibroblast growth factor receptor antagonist00low000000
tolmetinaromatic ketone;
monocarboxylic acid;
pyrroles
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
00low000000
zomepiracaromatic ketone;
monocarboxylic acid;
monochlorobenzenes;
pyrroles
cardiovascular drug;
non-steroidal anti-inflammatory drug
00low000000
n-methylpyrrolepyrroles00low000000
2,5-dimethylpyrrolepyrroles00low000000
pyrrole-2-carboxaldehyde1,3-thiazole-2-carbaldehyde;
pyrroles
00low000000
pyrrolnitrinalkaloid;
C-nitro compound;
monochlorobenzenes;
pyrroles
antifungal drug;
bacterial metabolite
00low000000
2-acetylpyrrolearomatic ketone;
methyl ketone;
pyrroles
00low000000
pyoluteorinaromatic ketone;
beta-hydroxy ketone;
diol;
organochlorine compound;
organochlorine pesticide;
polyketide;
pyrroles;
resorcinols
antibacterial agent;
antifungal agent;
apoptosis inducer;
bacterial metabolite;
marine metabolite
00low000000
clopiracpyrroles00low000000
fendosalbenzoindole;
monohydroxybenzoic acid;
pyrroles
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
00low000000
atorvastatinaromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic)
environmental contaminant;
xenobiotic
00low000000
ro 5-33351,4-benzodiazepinone;
organochlorine compound;
pyrroles
anti-HIV-1 agent;
antineoplastic agent;
HIV-1 Tat inhibitor;
RUNX1 inhibitor
00low000000
fludioxonilbenzodioxoles;
nitrile;
organofluorine compound;
pyrroles
androgen antagonist;
antifungal agrochemical;
estrogen receptor agonist
00low000000
fenpiclonildichlorobenzene;
nitrile;
pyrroles
antifungal agrochemical00low000000
chlorfenapyrhemiaminal ether;
monochlorobenzenes;
nitrile;
organochlorine acaricide;
organochlorine insecticide;
organofluorine acaricide;
organofluorine insecticide;
pyrroles
proacaricide;
proinsecticide
00low000000
pyrrolomycin aantibiotic antifungal agent;
C-nitro compound;
organochlorine compound;
pyrroles
antibacterial agent;
bacterial metabolite
00low000000
Ethyl 2,5-dimethyl-1H-pyrrole-3-carboxylatepyrroles00low000000
sceptrinpyrroles;
secondary carboxamide
00low000000
4-bromo-2-(4-chlorophenyl)-5-(trifluoromethyl)-1h-pyrrole-3-carbonitrilemonochlorobenzenes;
nitrile;
organobromine compound;
organochlorine acaricide;
organochlorine insecticide;
organofluorine acaricide;
organofluorine insecticide;
pyrroles
acaricide;
antifouling biocide;
insecticide
00low000000
orantinibmonocarboxylic acid;
oxindoles;
pyrroles
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
00low000000
4-(2-methyl-5-phenyl-1-pyrrolyl)benzoic acidpyrroles00low000000
pentabromopseudilinpyrrolesmetabolite00low000000
2,6-bis(2-hydroxyphenyl)pyrrolo[3,4-f]isoindole-1,3,5,7-tetronepyrroles00low000000
3-(2,5-dimethyl-1-pyrrolyl)-4-methylanilinepyrroles00low000000
2-[[3-acetyl-1-[4-(dimethylamino)phenyl]-2-methyl-5-indolyl]oxy]acetamidepyrroles00low000000
3-[1-(2-furanylmethyl)-5-phenyl-2-pyrrolyl]propanoic acidpyrroles00low000000
LSM-23602pyrroles00low000000
1-[1-(4-fluorophenyl)-2,5-dimethyl-3-pyrrolyl]-2-(4-methyl-1-piperidinyl)ethanonepyrroles00low000000
2-methyl-5-(1,4,5,7-tetramethyl-6-pyrrolo[3,4-d]pyridazinyl)anilinepyrroles00low000000
3-[1-(carboxymethyl)-5-phenyl-2-pyrrolyl]propanoic acidpyrroles00low000000
2-(4-fluorophenyl)-8-methylindolizinepyrroles00low000000
2-(1,4,5,7-tetramethyl-6-pyrrolo[3,4-d]pyridazinyl)anilinepyrroles00low000000
3-(3-formyl-2,5-dimethyl-1-pyrrolyl)-4-methylbenzoic acid methyl esterpyrroles00low000000
3-[5-(4-fluorophenyl)-1-(2-furanylmethyl)-2-pyrrolyl]propanoic acidpyrroles00low000000
3-[5-(4-methoxyphenyl)-1-prop-2-enyl-2-pyrrolyl]propanoic acidpyrroles00low000000
2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid methyl esterpyrroles00low000000
1-[2,5-dimethyl-1-(4-methylphenyl)-3-pyrrolyl]-2-([1,2,4]triazolo[4,3-a]pyridin-3-ylthio)ethanonepyrroles00low000000
7-(diethylaminomethyl)-1-(4-methoxyphenyl)-2-methyl-3-nitro-6-indololpyrroles00low000000
5-(2-amino-4-thiazolyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid methyl esterpyrroles00low000000
2-(4-fluorophenyl)-1-indolizinecarboxylic acid ethyl esterpyrroles00low000000
4-[7-(4-methylphenyl)-5-phenyl-4-pyrrolo[2,3-d]pyrimidinyl]morpholinepyrroles00low000000
4-[7-(3-methylphenyl)-5-phenyl-4-pyrrolo[2,3-d]pyrimidinyl]morpholinepyrroles00low000000
2-amino-N-(3-ethoxypropyl)-1-(4-sulfamoylphenyl)-3-pyrrolo[3,2-b]quinoxalinecarboxamidepyrroles00low000000
6-(4-hydroxyphenyl)-5-(4-methoxyphenyl)-1,3-dimethylpyrrolo[3,4-d]pyrimidine-2,4-dionepyrroles00low000000
1-[1-(4-methoxyphenyl)-2,5-dimethyl-3-pyrrolyl]-2-[(5-thiophen-2-yl-1,3,4-oxadiazol-2-yl)thio]ethanonepyrroles00low000000
N-[4-[[2-[1-(4-methoxyphenyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl]thio]phenyl]acetamidepyrroles00low000000
3-[1-(3-methoxypropyl)-5-thiophen-2-yl-2-pyrrolyl]propanoic acidpyrroles00low000000
3-(2,5-dimethyl-1-phenyl-3-pyrrolyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepinepyrroles00low000000
1-[1-(2-fluorophenyl)-2,5-dimethyl-3-pyrrolyl]-2-(4-methyl-1-piperidinyl)ethanonepyrroles00low000000
3-[5-(2,5-dimethyl-1-phenyl-3-pyrrolyl)-1,3,4-oxadiazol-2-yl]-1-benzopyran-2-onepyrroles00low000000
2-Chloro-1-[2,5-dimethyl-1-(3-nitrophenyl)-1H-pyrrol-3-yl]ethan-1-onepyrrolesanticoronaviral agent00low000000
4-hydroxybenzoic acid [2-[1-(2-fluorophenyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl] esterpyrroles00low000000
1-[1-(3-fluorophenyl)-2,5-dimethyl-3-pyrrolyl]-2-[(1-methyl-5-tetrazolyl)thio]ethanonepyrroles00low000000
2,4-diaziran-1-yl-6-(1-phenyl-1H-pyrrol-2-yl)-1,3,5-triazinepyrroles00low000000
3-[5-(4-methylphenyl)-1-(2-oxolanylmethyl)-2-pyrrolyl]propanoic acidpyrroles00low000000
3-[5-(4-methoxyphenyl)-1-(2-oxolanylmethyl)-2-pyrrolyl]propanoic acidpyrroles00low000000
3-[5-(4-fluorophenyl)-1-(2-oxolanylmethyl)-2-pyrrolyl]propanoic acidpyrroles00low000000
1-[1-(4-methoxyphenyl)-2,5-dimethyl-3-pyrrolyl]-2-[[4-methyl-5-(2-methyl-3-furanyl)-1,2,4-triazol-3-yl]thio]ethanonepyrroles00low000000
2-[2-(2,5-dimethyl-1-phenyl-3-pyrrolyl)-2-oxoethyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dionepyrroles00low000000
6-(3,4-dimethoxyphenyl)-4-oxo-3-phenyl-1,5,6,7-tetrahydroindole-2-carboxylic acid ethyl esterpyrroles00low000000
N-[2-(tert-butylamino)-2-oxo-1-thiophen-2-ylethyl]-N-(2-oxolanylmethyl)-5-phenyl-1H-pyrrole-2-carboxamidepyrroles00low000000
N-[2-(tert-butylamino)-2-oxo-1-pyridin-4-ylethyl]-N-(2-furanylmethyl)-5-phenyl-1H-pyrrole-2-carboxamidepyrroles00low000000
2-(3-ethoxycarbonyl-2-methyl-5-phenyl-1-pyrrolyl)acetic acidpyrroles00low000000
2-(3-acetyl-2-methyl-5-phenyl-1-pyrrolyl)-N-(thiophen-2-ylmethyl)acetamidepyrroles00low000000
4-[dimethylamino(oxo)methyl]-3,5-dimethyl-1H-pyrrole-2-carboxylic acid ethyl esterethyl ester;
pyrroles;
tertiary carboxamide
00low000000
1-[3-[2-(dimethylamino)ethylamino]-3-oxopropyl]-2-methyl-5-(4-methylphenyl)-3-pyrrolecarboxylic acid ethyl esterpyrroles00low000000
3-(1-methyl-2-benzimidazolyl)-1-phenyl-2-pyrrolo[3,2-b]quinoxalinaminepyrroles00low000000
2-[[7-(4-methoxyphenyl)-5-phenyl-4-pyrrolo[2,3-d]pyrimidinyl]thio]propanoic acid ethyl esterpyrroles00low000000
7-butyl-6-(4-methoxyphenyl)-5H-pyrrolo[2,3-b]pyrazinepyrroles00low000000
N-cyclohexyl-1-(4-fluorophenyl)-2,5-dimethyl-3-pyrrolecarboxamidepyrroles00low000000
6-oxo-4,5-dihydro-1H-pyridazine-3-carboxylic acid [1-[1-[4-(difluoromethoxy)phenyl]-2,5-dimethyl-3-pyrrolyl]-1-oxopropan-2-yl] esterpyrroles00low000000
N-(cyclopentylideneamino)-4-(2,5-dimethyl-1-pyrrolyl)benzamidepyrroles00low000000
5-[(3-methylphenoxy)methyl]-3-[4-(1-pyrrolyl)phenyl]-1,2,4-oxadiazolepyrroles00low000000
1-[1-(4-methoxyphenyl)-2,5-dimethyl-3-pyrrolyl]-2-[(6-methyl-2-nitro-3-pyridinyl)oxy]ethanonepyrroles00low000000
3'-[2-[1-(4-methoxyphenyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl]spiro[6,7-dihydro-5H-1-benzothiophene-4,5'-imidazolidine]-2',4'-dionepyrroles00low000000
3-(1-methyl-2-benzimidazolyl)-1-(3-methylphenyl)-2-pyrrolo[3,2-b]quinoxalinaminepyrroles00low000000
semaxinibolefinic compound;
oxindoles;
pyrroles
angiogenesis modulating agent;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
00low000000
su 11248monocarboxylic acid amide;
pyrroles
angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
00low000000
oroidinpyrroles;
secondary carboxamide
metabolite00low000000
su 5614organochlorine compound;
oxindoles;
pyrroles
vascular endothelial growth factor receptor antagonist00low000000
ageladine aalkaloid;
aromatic amine;
imidazopyridine;
organobromine compound;
pyrroles
angiogenesis inhibitor;
antineoplastic agent;
matrix metalloproteinase inhibitor;
metabolite
00low000000
vonoprazanpyrroles00low000000
4-(2-phenylethylsulfamoyl)-1H-pyrrole-2-carboxylic acid methyl esterpyrroles00low000000
marinopyrrole aaromatic ketone;
organochlorine compound;
phenols;
pyrroles
antibacterial agent;
antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
marine metabolite
00low000000
coumermycinaromatic amide;
coumarins;
glycoside;
heteroarenecarboxylate ester;
pyrroles
antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
DNA synthesis inhibitor;
Hsp90 inhibitor;
topoisomerase IV inhibitor
00low000000
1-[4-amino-7-[3-(2-methoxyethylamino)propyl]-5-(4-methylphenyl)-6-pyrrolo[2,3-d]pyrimidinyl]-2-fluoroethanonepyrroles00low000000
saroglitazararomatic ether;
methyl sulfide;
monocarboxylic acid;
pyrroles
hypoglycemic agent;
PPARalpha agonist;
PPARgamma agonist
00low000000
5-[1-(4-chlorophenyl)-2,5-dimethyl-3-pyrrolyl]-N-methyl-6H-1,3,4-thiadiazin-2-aminepyrroles00low000000
marineosin aazaspiro compound;
ether;
macrocycle;
oxaspiro compound;
pyrroles
antineoplastic agent;
metabolite
00low000000
marineosin bazaspiro compound;
ether;
macrocycle;
oxaspiro compound;
pyrroles
antineoplastic agent;
metabolite
00low000000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
pd 173074aromatic amine;
biaryl;
dimethoxybenzene;
pyridopyrimidine;
tertiary amino compound;
ureas
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist
2007200717.0low000100
4,5,6,7-tetrabromo-2-azabenzimidazole2007200717.0low000100
N-(2-aminoethyl)-5-chloro-1-naphthalenesulfonamidenaphthalenes;
sulfonic acid derivative
2007200717.0low000100
tyrphostin ag 1024alkylbenzene2013201311.0low000010
ag 1295quinoxaline derivativegeroprotector2007201314.0medium000110
ag-1296quinoxaline derivative2013201311.0low000010
rtki cpdaromatic ether;
monochlorobenzenes;
quinazolines
antineoplastic agent;
antiviral agent;
epidermal growth factor receptor antagonist;
geroprotector
2013201311.0low000010
tyrphostin a23catechols2007200717.0low000100
tyrphostin a1methoxybenzenesgeroprotector2013201311.0low000010
bisindolylmaleimide i2004201316.0low000210
bisindolylmaleimide ivindoles;
maleimides
2007201314.0medium000110
boheminepurinesEC 2.7.11.22 (cyclin-dependent kinase) inhibitor2007201314.0low000110
chelerythrinebenzophenanthridine alkaloid;
organic cation
antibacterial agent;
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
2007201314.0low000110
damnacanthalaldehyde;
monohydroxyanthraquinone
2007200717.0low000100
r 59022diarylmethane2007200717.0low000100
n(6),n(6)-dimethyladeninetertiary amine2007200717.0low000100
ellipticineindole alkaloid;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound;
polycyclic heteroarene
antineoplastic agent;
plant metabolite
2007200717.0low000100
gö6983indoles;
maleimides
2013201311.0low000010
go 6976indolocarbazole;
organic heterohexacyclic compound
EC 2.7.11.13 (protein kinase C) inhibitor2007201314.0low000110
ha 1004isoquinolines2007200717.0low000100
fasudilisoquinolines;
N-sulfonyldiazepane
antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent
2007201314.0low000110
indirubin-3'-monoxime2004201315.2low000220
whi p1542013201311.0low000010
1-(2-naphthalenyl)-3-[(phenylmethyl)-propan-2-ylamino]-1-propanonenaphthalenes2013201311.0low000010
nsc 664704indolobenzazepine;
lactam;
organobromine compound
cardioprotective agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
geroprotector
2004202112.8low000211
lavendustin aaromatic amine2007200717.0low000100
2-hydroxy-5-(2,5-dihydrobenzyl)aminobenzoic acidaromatic amine2007200717.0low000100
ly 303511N-arylpiperazine2013201311.0low000010
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-onechromones;
morpholines;
organochlorine compound
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector
2007201314.0low000110
ml 9naphthalenes;
sulfonic acid derivative
2007200717.0low000100
nu61022007200717.0low000100
olomoucine2,6-diaminopurines;
ethanolamines
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor2007200717.0low000100
pd 153035aromatic amine;
aromatic ether;
bromobenzenes;
quinazolines;
secondary amino compound
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist
2007200717.0low000100
pd 158780aromatic amine;
bromobenzenes;
diamine;
pyridopyrimidine;
secondary amino compound
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
2013201311.0low000010
pd 169316imidazoles2007201314.0low000110
pd 98059aromatic amine;
monomethoxyflavone
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
2007201314.0low000110
1-NA-PP1pyrazolopyrimidinetyrosine kinase inhibitor2007200717.0low000100
ag 1879aromatic amine;
monochlorobenzenes;
pyrazolopyrimidine
beta-adrenergic antagonist;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector
2007200717.0low000100
1-phenyl-4-pyrazolo[3,4-d]pyrimidinaminepyrazoles;
ring assembly
2013201311.0low000010
ro 31-8220imidothiocarbamic ester;
indoles;
maleimides
EC 2.7.11.13 (protein kinase C) inhibitor2004200420.0low000100
sb 220025aminopyrimidine;
imidazoles;
organofluorine compound;
piperidines
angiogenesis inhibitor;
anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
2007201314.0low000110
sb 239063imidazoles2007200717.0low000100
sb 202190imidazoles;
organofluorine compound;
phenols;
pyridines
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
2007201314.0low000110
sk&f 86002imidazoles2013201311.0low000010
whi p1802007200717.0low000100
zm 336372benzamides2007200717.0low000100
dichlororibofuranosylbenzimidazole2007200717.0low000100
pyrazolanthroneanthrapyrazole;
aromatic ketone;
cyclic ketone
antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector
2007201313.7low000120
1,4-naphthoquinone1,4-naphthoquinones2007200717.0low000100
staurosporineindolocarbazole alkaloid;
organic heterooctacyclic compound
apoptosis inducer;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
geroprotector
2004201913.2low000230
arctigeninlignan2007200717.0low000100
triciribinenucleoside analogueEC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor2013201311.0low000010
chelerythrine chloride2007200717.0low000100
fascaplysine2007200717.0low000100
LSM-4272beta-carbolines2013201311.0low000010
5-iodotubercidinorganoiodine compound2007200717.0low000100
imatinib mesylatemethanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
2007200717.0low000100
gefitinibaromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound
antineoplastic agent;
epidermal growth factor receptor antagonist
2007200717.0low000100
pomalidomidearomatic amine;
dicarboximide;
isoindoles;
piperidones
angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
202120213.0low000001
vatalanibmonochlorobenzenes;
phthalazines;
pyridines;
secondary amino compound
angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
2007200717.0low000100
ruboxistaurin2007200717.0low000100
cyc 2022,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
2007200717.0low000100
sb 203580imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
2007201314.0low000110
sb 216763indoles;
maleimides
200420219.3low000111
erlotinibaromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound
antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor
2007200717.0low000100
5-iodoindirubin-3'-monoxime2007200717.0medium000100
2H-pyrazolo[4,3-b]quinoxalin-3-aminequinoxaline derivative2007201313.7high000120
hts 466284pyrazoles;
pyridines;
quinolines
TGFbeta receptor antagonist2013201311.0low000010
n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea2004201316.0low000210
y 27632aromatic amide2007201314.0low000110
h 1152isoquinolines;
N-sulfonyldiazepane
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor2007200717.0medium000100
7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine2004201316.0high000210
6-bromoindirubin-3'-oxime2004201315.2low000220
h 89N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide2007201314.0low000110
purvalanol apurvalanol2007201314.0low000110
2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dioneaminotoluene2007201314.0high000110
evp 45932013201311.0low000010
cgp 60474substituted aniline2004200420.0low000100
3-(4-pyridyl)-1h-indoleindoles2013201311.0medium000010
r 59949diarylmethane2007201314.0low000110
3,3',4,5'-tetrahydroxystilbenecatechols;
polyphenol;
resorcinols;
stilbenol
antineoplastic agent;
apoptosis inducer;
geroprotector;
hypoglycemic agent;
plant metabolite;
protein kinase inhibitor;
tyrosine kinase inhibitor
2007200717.0low000100
3,4-methylenedioxy-beta-nitrostyrene2013201311.0low000010
4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenolsubstituted aniline2013201311.0low000010
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamidenaphthalenecarboxamide2013201311.0low000010
2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamidedimethoxybenzene2013201311.0medium000010
Src Inhibitor-1aromatic ether;
polyether;
quinazolines;
secondary amino compound
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor2013201311.0low000010
tg 0032007201314.0low000110
N-[2-[5-(1,3-benzothiazol-2-yl)-3-ethyl-1-phenyl-2-benzimidazol-3-iumyl]ethenyl]-N-methylanilinebenzimidazoles2013201311.0medium000010
thioureaone-carbon compound;
thioureas;
ureas
antioxidant;
chromophore
2007200717.0low000100
cgp 74514a2011201312.0medium000020
1,4-dimethoxy-10H-acridine-9-thioneacridines2013201311.0medium000010
u 0126aryl sulfide;
dinitrile;
enamine;
substituted aniline
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent
2007200717.0low000100
sf 2370bridged compound;
gamma-lactam;
methyl ester;
organic heterooctacyclic compound
antimicrobial agent;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
tropomyosin-related kinase B receptor antagonist
2013201311.0low000010
dasatinib1,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound
anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
2007200717.0low000100
gtp 14564pyrazoles;
ring assembly
2007201314.0high000110
sb 218078indolocarbazole2007201314.0medium000110
sto 609naphthoic acid2011201312.0low000020
7-butyl-6-(4-methoxyphenyl)-5H-pyrrolo[2,3-b]pyrazinepyrroles2013201311.0medium000010
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dionebenzenes;
thiadiazolidine
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent
2004202111.3low000111
sb 415286C-nitro compound;
maleimides;
monochlorobenzenes;
phenols;
secondary amino compound;
substituted aniline
antioxidant;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent
2004200420.0low000100
alsterpaulloneC-nitro compound;
caprolactams;
organic heterotetracyclic compound
anti-HIV-1 agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor
2004202112.8low000211
1-tert-butyl-3-naphthalen-1-ylmethyl-1h-pyrazolo(3,4-d)pyrimidin-4-yleminepyrazolopyrimidinetyrosine kinase inhibitor2013201311.0low000010
ku 559332013201311.0low000010
quercetin7-hydroxyflavonol;
pentahydroxyflavone
antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
2007200717.0low000100
apigenintrihydroxyflavoneantineoplastic agent;
metabolite
2007200717.0low000100
daphnetinhydroxycoumarin2007200717.0low000100
genistein7-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
2007200717.0low000100
wedelolactonearomatic ether;
coumestans;
delta-lactone;
polyphenol
antineoplastic agent;
apoptosis inducer;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
hepatoprotective agent;
metabolite
2007200717.0low000100
purmorphaminearomatic ether;
morpholines;
purines;
secondary amino compound
osteogenesis regulator;
SMO receptor agonist
2005200519.0low000100
sirolimusantibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol
antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
2013201311.0low000010
as 6048502013201311.0low000010
alvocidibdihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound
antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
2004200420.0low000100
geldanamycin1,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound
antimicrobial agent;
antineoplastic agent;
antiviral agent;
cysteine protease inhibitor;
Hsp90 inhibitor
2007200717.0low000100
su 95162004201315.2medium000220
3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamidepyrimidines2013201311.0low000010
kn 93monochlorobenzenes;
monomethoxybenzene;
primary alcohol;
sulfonamide;
tertiary amino compound
EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitor;
geroprotector
2007201314.0low000110
kn 62piperazines2013201311.0low000010
su 66562007201314.0low000110
fexaraminebiphenyls2005200519.0low000100
tyrphostin ag-4942007200717.0low000100
ag-490catechols;
enamide;
monocarboxylic acid amide;
nitrile;
secondary carboxamide
anti-inflammatory agent;
antioxidant;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector;
STAT3 inhibitor
2007201314.0low000110
ag 1122013201311.0low000010
semaxinibolefinic compound;
oxindoles;
pyrroles
angiogenesis modulating agent;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
2013201311.0low000010
su 11248monocarboxylic acid amide;
pyrroles
angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
2007200717.0low000100
su 11652olefinic compound;
organochlorine compound;
oxindoles;
pyrrolecarboxamide;
tertiary amino compound
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor
2007201314.0medium000110
6-(4-methoxyphenyl)-3-(3-thiophenyl)pyrazolo[1,5-a]pyrimidinepyrimidines2013201311.0high000010
jnj-7706621sulfonamide2013201311.0low000010
bay 11-7082nitrile;
sulfone
apoptosis inducer;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor
2013201311.0low000010
2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-oneorganic heterotetracyclic compound;
organofluorine compound
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor2007201314.0low000110
st 6382007200717.0low000100
su 1498enamide;
monocarboxylic acid amide;
nitrile;
phenols;
secondary carboxamide
vascular endothelial growth factor receptor antagonist2007200717.0low000100
monordencyclic ketone;
enone;
epoxide;
macrolide antibiotic;
monochlorobenzenes;
phenols
antifungal agent;
metabolite;
tyrosine kinase inhibitor
2007200717.0low000100
ml 34032007201314.0high000110
d 4476imidazoles2007201314.0medium000110
GSK3-XIIIaromatic amine;
pyrazoles;
quinazolines;
secondary amino compound
EC 2.7.11.26 (tau-protein kinase) inhibitor2007201313.7high000120
herbimycin2013201311.0medium000010
su 43122013201311.0low000010
1-azakenpaullonelactam;
organic heterotetracyclic compound;
organobromine compound;
organonitrogen heterocyclic compound
EC 2.7.11.26 (tau-protein kinase) inhibitor;
Wnt signalling activator
2004200420.0medium000100
2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazolearyl sulfide2004201316.0high000210
b 43aromatic amine;
aromatic ether;
cyclopentanes;
primary amino compound;
pyrrolopyrimidine
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector
2013201311.0low000010
aminopurvalanol amonochlorobenzenes;
purvalanol
protein kinase inhibitor2007201314.0high000110
cgk 733diarylmethane2013201311.0low000010
tubacin1,3-oxazoles2005200519.0low000100
cgp 53353phthalimides2013201311.0low000010
cvt 3132007201314.0medium000110
bibx 1382bssubstituted aniline2007200717.0low000100
sl 3272007200717.0low000100
krn 6332007200717.0low000100
((3z)-n-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1h-pyrrol-2-yl)methylene)-n-methyl-2-oxo-2,3-dihydro-1h-indole-5-sulfonamide)sulfonamide2007200717.0low000100
c 13682007201313.7high000120
pq 401quinolines2007201314.0medium000110
jnj 101984092007201314.0high000110
midostaurinbenzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
2013201311.0low000010
sb-505124benzodioxole;
imidazoles;
methylpyridines
TGFbeta receptor antagonist2013201311.0low000010
ic 86621aromatic ketone2013201311.0medium000010
nu 7026organic heterotricyclic compound;
organooxygen compound
2007201314.0low000110
pi103aromatic amine;
morpholines;
organic heterotricyclic compound;
phenols;
tertiary amino compound
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
2007201314.0low000110
y 27632, dihydrochloride, (4(r)-trans)-isomer2007200717.0medium000100
2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamidearomatic amide;
thiophenes
2011201312.0low000020
tivozanibaromatic ether2013201311.0low000010
chir 99021aminopyridine;
aminopyrimidine;
cyanopyridine;
diamine;
dichlorobenzene;
imidazoles;
secondary amino compound
EC 2.7.11.26 (tau-protein kinase) inhibitor2004202111.5low000101
azd2858aromatic amine;
N-methylpiperazine;
pyrazines;
pyridines;
secondary carboxamide;
sulfonamide
antineoplastic agent;
bone density conservation agent;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
Wnt signalling activator
202120213.0medium000001
nu 61402011201312.0medium000020
PDGF receptor tyrosine kinase inhibitor IIIaromatic ether;
N-arylpiperazine;
N-carbamoylpiperazine;
phenylureas;
quinazolines;
tertiary amino compound
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor2013201311.0high000010
np 031112benzenes;
naphthalenes;
thiadiazolidine
anti-inflammatory agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent
202120213.0low000001
cardiogenol cmethoxybenzenes;
substituted aniline
2005200519.0low000100
4-[4-(2-fluorophenyl)phenyl]-N-(4-hydroxyphenyl)butanamidebiphenyls2013201311.0high000010
fr 180204pyrazoles;
ring assembly
2007201314.0low000110
dorsomorphinaromatic ether;
piperidines;
pyrazolopyrimidine;
pyridines
bone morphogenetic protein receptor antagonist;
EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
2011201312.0low000020
ki11502aromatic ether;
benzamides;
quinolines;
thioureas
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
2013201311.0medium000010
gw 25802007201314.0low000110
cgp 57380pyrazolopyrimidine2011201312.0low000020
(e)-3-(2,3,4,5-tetrabromophenyl)acrylic acid2011201312.0high000020
lfm a13aromatic amide;
dibromobenzene;
enamide;
enol;
nitrile;
secondary carboxamide
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 2.7.11.21 (polo kinase) inhibitor;
geroprotector;
platelet aggregation inhibitor
2007200717.0low000100
akt-i-1,2 compound2013201311.0low000010
hymenialdisine2004200718.5low000200
isogranulatimide2007201313.7medium000120
6-bromoindirubin-3'-acetoxime2013201311.0high000010
debromohymenialdisine2007200717.0low000100
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
adenine6-aminopurines;
purine nucleobase
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
201920195.0low000010
ureaisourea;
monocarboxylic acid amide;
one-carbon compound
Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
201620168.0low000010
1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-oneoxadiazoloquinoxalineEC 4.6.1.2 (guanylate cyclase) inhibitor201920195.0low000010
chloroquineaminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound
anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
202020204.0low000010
serineL-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine
algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
201620168.0low000010
threonineamino acid zwitterion;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
threonine
algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
201620168.0low000010
quinoxalinesmancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene
201920195.0low000010
pyrrolespyrrole;
secondary amine
201020217.7low0001192
thiazoles1,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
201620168.0low000010
glutamic acidglutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid
Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
202120213.0low000001
1-((3,5-dichloro)-2,6-dihydroxy-4-methoxyphenyl)-1-hexanonedichlorobenzene;
differentiation-inducing factor;
monomethoxybenzene;
resorcinols
eukaryotic metabolite;
signalling molecule
201920195.0low000010
sb 216763indoles;
maleimides
202020204.0low000010
leupeptins202020204.0low000010
lithium chlorideinorganic chloride;
lithium salt
antimanic drug;
geroprotector
201920204.5low000020
n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea201620168.0low000010
benzyloxycarbonylleucyl-leucyl-leucine aldehydeamino aldehyde;
carbamate ester;
tripeptide
proteasome inhibitor202020204.0low000010
cardamoninchalcones2013201311.0low000010
tamoxifenstilbenoid;
tertiary amino compound
angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
201820186.0low000010
sirolimusantibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol
antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
2013201311.0low000010
bafilomycin a202020204.0low000010
oxadiazoles201920195.0low000010
9-(tetrahydro-2-furyl)-adenine201920195.0low000010
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Benign Neoplasms02004200420.0low000100
Congenital Zika Syndrome0202020204.0low000010
Degenerative Diseases, Central Nervous System0202120213.0low000001
Diabetes Mellitus, Adult-Onset02004200420.0low000100
Diabetes Mellitus, Type 202004200420.0low000100
Disease Models, Animal0202020204.0low000010
Neoplasms02004200420.0low000100
Nervous System Diseases02004200420.0low000100
Nervous System Disorders02004200420.0low000100
Neurodegenerative Diseases0202120213.0low000001
Parasite Infections02004200420.0low000100
Zika Virus Infection0202020204.0low000010
Acute Brain Injuries0202120213.0low000001
Anoxia-Ischemia, Brain0202120213.0low000001
Anterior Circulation Transient Ischemic Attack0201720177.0low000010
Apoplexy0201620196.7low000030
Brain Edema0201620168.0low000010
Brain Hemorrhage, Cerebral0201620168.0low000010
Brain Injuries0202120213.0low000001
Brain Ischemia0201620168.0low000010
Brain Swelling0201620168.0low000010
Cancer of Colon0201820186.0low000010
Cancer of Lung0201220189.0low000020
Carcinoma, Non-Small Cell Lung0201820186.0low000010
Carcinoma, Non-Small-Cell Lung0201820186.0low000010
Cardiac Remodeling, Ventricular0201720177.0low000010
Cerebral Hemorrhage0201620168.0low000010
Cerebral Infarction, Middle Cerebral Artery0201620177.5low000020
Cerebral Ischemia0201620168.0low000010
Cirrhosis0201720177.0low000010
Cirrhosis, Liver0201920195.0low000010
Colonic Neoplasms0201820186.0low000010
Degenerative Diseases, Central Nervous System0202120213.0low000001
Diabetic Retinopathy0202120213.0low000001
Disease Models, Animal0201720186.5low000020
Encapsulating Peritoneal Sclerosis0201820186.0low000010
ER-Negative PR-Negative HER2-Negative Breast Cancer0201920195.0low000010
Fibrosis0201720177.0low000010
Hypoxia-Ischemia, Brain0202120213.0low000001
Infarction, Middle Cerebral Artery0201620177.5low000020
Inflammation0202120213.0low000001
Innate Inflammatory Response0202120213.0low000001
Ischemic Attack, Transient0201720177.0low000010
Leucocythaemia02013201311.0low000010
Leukemia02013201311.0low000010
Liver Cirrhosis0201920195.0low000010
Lung Neoplasms0201220189.0low000020
Neurodegenerative Diseases0202120213.0low000001
Rhabdomyosarcoma 202010201014.0low000100
Rhabdomyosarcoma, Alveolar02010201014.0low000100
Stroke0201620196.7low000030
Triple Negative Breast Neoplasms0201920195.0low000010

Safety/Toxicity (1)

ArticleYear
Involvement of oncogenic protein β-catenin in LPS-induced cytotoxicity in mouse mononuclear leukemia RAW 264.7 cells.
Oncology research, , Volume: 21, Issue:1
2013

Bioavailability (1)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5
2019